Pyrazolam
From Wikipedia, the free encyclopedia
 |
|
| Clinical data | |
|---|---|
| Routes of administration |
Oral, Sublingual, rectal |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Biological half-life | 17 hours |
| Identifiers | |
|
|
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C16H12BrN5 |
| Molar mass | 354.204 g/mol |
| 3D model (JSmol) | |
|
|
|
|
Pyrazolam is a benzodiazepine derivative originally developed by a team led by Leo Sternbach at Hoffman-La Roche in the 1970s,[1] and subsequently "rediscovered" and sold as a designer drug starting in 2012.[2][3][4][5]
Pyrazolam has structural similarities to alprazolam[6] and bromazepam. Unlike other benzodiazepines, pyrazolam does not appear to undergo metabolism, instead being excreted unchanged in the urine.[2][7] It is most selective for the α2 and α3 subtypes of the GABAA receptor.[8]
Legal Status[edit]
United Kingdom[edit]
In the UK, pyrazolam has been classified as a Class C drug by section 5 of the May 2017 amendment to The Misuse of Drugs Act 1971 along with several other designer benzodiazepine drugs.[9]
See also[edit]
References[edit]
- ^ US 3954728, "Preparation of triazolo benzodiazepines and novel compounds"
- ^ a b Moosmann, B.; Hutter, M.; Huppertz, L. M.; Ferlaino, S.; Redlingshöfer, L.; Auwärter, V. (July 2013). "Characterization of the designer benzodiazepine pyrazolam and its detectability in human serum and urine". Forensic Toxicology. 31 (2): 263–271. doi:10.1007/s11419-013-0187-4.
- ^ Bjoern Moosmann; Leslie A King; Volker Auwärter (June 2015). "Designer benzodiazepines: A new challenge". World Psychiatry. 14 (2): 248. PMC 4471986
. PMID 26043347. doi:10.1002/wps.20236. - ^ Madeleine Pettersson Bergstrand; Anders Helander; Therese Hansson; Olof Beck (2016). "Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays". Drug Testing and Analysis. PMID 27366870. doi:10.1002/dta.2003.
- ^ Høiseth, Gudrun; Tuv, Silja Skogstad; Karinen, Ritva (2016). "Blood concentrations of new designer benzodiazepines in forensic cases". Forensic Science International. 268: 35–38. PMID 27685473. doi:10.1016/j.forsciint.2016.09.006.
- ^ Hester Jr, J. B.; Rudzik, A. D.; Kamdar, B. V. (November 1971). "6-Phenyl-4H-s-triazolo[4,3-a][l,4]benzodiazepines Which Have Central Nervous System Depressant Activity". J. Med. Chem. 14 (11): 1078–1081. PMID 5165540. doi:10.1021/jm00293a015.
- ^ Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples, B. Moosmann, M. Hutter, L. M. Huppertz and V. Auwärter
- ^ Hester, J. B.; von Voigtlander, P. (November 1979). "6-Aryl-4H-s-triazolo[4,3-a][1,4]benzodiazepines. Influence of 1-substitution on pharmacological activity". Journal of Medicinal Chemistry. 22 (11): 1390–1398. PMID 42799. doi:10.1021/jm00197a021.
- ^ "The Misuse of Drugs Act 1971 (Amendment) Order 2017".
